ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2017
The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Economics of Antibiotic Resistance: A Systematic Review and Meta-analysis Based on Global Research.Applied health economics and health policy · 2026Pooled it
- Pooled it
- The incidence and prevalence of hospital-acquired (carbapenem-resistant)Emerging microbes & infections · 2019Pooled it
- Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.Antimicrobial resistance and infection control · 2019Pooled it
- The global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2025Review
- Economic costing methodologies for drug-resistant bacterial infections in humans in low-and middle-income countries: a systematic review.Health economics review · 2025Review
- Development and application of a risk nomogram for the prediction of risk of carbapenem-resistant Acinetobacter baumannii infections in neuro-intensive care unit: a mixed method study.Antimicrobial resistance and infection control · 2024Article
- Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2022Review
- The Economic Impact of Carbapenem Resistant-Non Lactose Fermenter andAntibiotics (Basel, Switzerland) · 2022Article
- Isolation and Characterisation of Bacteriophage Selective for KeyPharmaceuticals (Basel, Switzerland) · 2022Article
- Epidemiology and infection control of carbapenem resistant Acinetobacter baumannii and Klebsiella pneumoniae at a German university hospital: a retrospective study of 5 years (2015-2019).BMC infectious diseases · 2021Article
- Economic burden of antibiotic resistance in China: a national level estimate for inpatients.Antimicrobial resistance and infection control · 2021Article
- Colonization With Extensively Drug-ResistantFrontiers in medicine · 2021Article
- Clinical and Economic Impact of Third-Generation Cephalosporin-Resistant Infection or Colonization Caused byInternational journal of environmental research and public health · 2020Article
- Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused byAntibiotics (Basel, Switzerland) · 2020Article
- The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-Net data from 2013 to 2017.Antimicrobial resistance and infection control · 2020Observational
- The Clinical and Economic Impact of Antibiotic Resistance in China: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2019Review
- Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistantAntimicrobial resistance and infection control · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study aims to compare differences in the medical costs between inpatients infected/colonised with carbapenem-resistant (CRAB) and carbapenem-susceptible (CSAB) Acinetobacter baumannii in a hospital in Zhejiang province, China. Because the patient population was large, we randomly selected 60% of all inpatients with clinical specimens between 2013 and 2015. We classified the A. baumannii cases as CRAB or CSAB based on antibiotic susceptibility testing. Univariate and multivariate analyses were used to identify factors associated with the total medical cost (TMC). Those included in the study totalled 2980 inpatients, 71.3% of whom had CRAB infection/colonisation. Differences in the TMC between the CRAB and CSAB groups were lower by multivariate analyses than the differences obtained by univariate analyses. Carbapenem resistance was significantly associated with an approximately 1.5-fold increase in the TMC after accounting for confounding factors. Our study highlights the heavy financial burden imposed by A. baumannii and carbapenem resistance on the Chinese healthcare system.
Indexed as
Identifiers
28831598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.